Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Bristol Myers Squibb (BMY) Stock Could Be 13% Undervalued As Pipeline Plans Take Shape - simplywall.st

AI-generated analysis

📈 BMY stock is trading at $54.70 with a recent 30-day return of -8.01% but a 1-year total shareholder return of 22.41%.

💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, yielding approximately 4.6%.

📊 Analysts estimate a fair value of $62.96, implying the stock is undervalued by roughly 13% based on discounted cash flow models.

🔬 Strategic partnerships with BioNTech and Philochem aim to expand pipeline breadth and offset patent expiries for key drugs like Eliquis and Opdivo.

⚖️ The current P/E ratio of 15.4x sits between the industry average of 14.9x and a fair peer-adjusted ratio of 18.6x.

⚠️ Significant risks include patent cliffs for major revenue drivers and ongoing pressure on pricing and margins in the U.S. market.

Bullish Signals
  • The company offers a 4.6% dividend yield with a declared quarterly payout of $0.63 per share.
  • Analyst fair value models suggest BMY is undervalued by approximately 13% relative to a target price of $62.96.
  • A robust late-stage pipeline and strategic partnerships are expected to support top-line growth and offset patent expiries.
Risk Factors
  • The stock faces meaningful risks from patent cliffs associated with key drugs like Eliquis and Opdivo.
  • Valuation metrics show mixed signals, with the current P/E ratio of 15.4x exceeding the industry average of 14.9x.
Full Analysis
Bristol-Myers Squibb (BMY) is currently trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company has declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026, offering a yield of approximately 4.6%. Analysts at Simply Wall St estimate BMY's fair value at $62.96, suggesting the stock is undervalued by roughly 13%. This valuation gap is attributed to a robust late-stage pipeline, strategic partnerships with entities like BioNTech and Philochem, and potential for label expansions that could offset upcoming patent expiries for major brands such as Eliquis and Opdivo. Despite the bullish fair value narrative, the stock faces mixed signals regarding valuation metrics. The current P/E ratio of 15.4x is slightly above the US pharmaceuticals industry average of 14.9x but below a calculated fair ratio of 18.6x and peer averages of 21.7x. Investors must weigh these potential upside drivers against significant risks including patent cliffs, pricing pressure in the core U.S. market, and shifting revenue mix dynamics.